{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARGX",
    "asset_name": "pipeline"
  },
  "asset": {
    "name": "Pipeline Assets",
    "company": "argenx SE",
    "ticker": "ARGX",
    "modality": "Multiple (antibodies, Fc fragments, sweeping antibodies)",
    "stage": "Phase 1 to Registrational",
    "one_liner": "Deep pipeline of 10 clinical-stage molecules including next-gen FcRn (ARGX-213), IgA sweeper (ARGX-121), and first-in-class MuSK agonist (adimanebart)",
    "ownership": "Wholly-owned and partnered"
  },
  "target": {
    "name": "Multiple Targets",
    "full_name": "FcRn, MuSK, IgA, IL-6, Galectin-10, Fn14",
    "class": "Various",
    "pathway": "Multiple immunology pathways",
    "biology": {
      "simple_explanation": "argenx's pipeline spans multiple immunology targets including next-generation FcRn inhibitors (ARGX-213, ARGX-124), the first IgA sweeping antibody (ARGX-121), a first-in-class MuSK agonist (adimanebart), and novel targets entering Phase 1 in 2026.",
      "innovation_engine": "25 active IIP programs; target of 1 IND per year"
    },
    "why_good_target": {
      "clinical_validation": "FcRn validated by VYVGART; other targets address unmet needs in autoimmune diseases",
      "unmet_need": [
        "Monthly FcRn dosing (ARGX-213) improves convenience",
        "IgA-mediated diseases lack targeted therapies",
        "Neuromuscular junction diseases need novel mechanisms"
      ]
    }
  },
  "pipeline_assets": {
    "adimanebart": {
      "internal_id": "ARGX-119",
      "target": "MuSK (muscle-specific kinase)",
      "modality": "MuSK agonist antibody",
      "stage": "Registrational",
      "indications": "CMS, ALS, SMA",
      "differentiation": "First-in-class MuSK agonist; enhances neuromuscular junction function"
    },
    "argx_213": {
      "target": "FcRn (sustained)",
      "modality": "Fc-ABDEG + anti-albumin VHH",
      "stage": "Phase 3 ready",
      "key_data": "Monthly dosing achieved; sustained 70-80% IgG reduction over 140+ days",
      "differentiation": "Monthly dosing vs weekly for efgartigimod SC; no IgG cycling",
      "potential_indications": "15+ (same as efgartigimod platform)"
    },
    "argx_121": {
      "target": "IgA",
      "modality": "IgA sweeping antibody",
      "stage": "Phase 1/PoC",
      "key_data": "Rapid and total IgA depletion within 7 days of single SC dose",
      "lead_indication": "IgA Nephropathy",
      "differentiation": "First IgA-specific sweeping antibody"
    },
    "argx_109": {
      "target": "IL-6",
      "modality": "Antibody",
      "stage": "PoC",
      "indications": "Multiple autoimmune/inflammatory diseases"
    },
    "argx_124": {
      "target": "FcRn",
      "modality": "Next-gen FcRn inhibitor",
      "stage": "Phase 1",
      "description": "FcRn franchise expansion"
    },
    "argx_118": {
      "target": "Galectin-10",
      "modality": "Antibody",
      "stage": "Phase 1 entering 2026",
      "description": "Novel target"
    },
    "argx_125": {
      "target": "Undisclosed",
      "modality": "TBD",
      "stage": "Phase 1 entering 2026"
    },
    "tsp_101": {
      "target": "Fn14",
      "modality": "Antibody",
      "stage": "Phase 1 entering 2026",
      "source": "In-licensed from Tensegrity"
    }
  },
  "indications": {
    "lead": {
      "name": "Multiple indications across pipeline",
      "stage": "Phase 1 to Registrational",
      "rationale": "Diversified pipeline reduces single-asset risk"
    }
  },
  "clinical_data": {
    "trial_name": "Multiple trials across pipeline",
    "trial_design": {
      "phase": "Phase 1 to Registrational",
      "design": "Various designs per program"
    },
    "argx_213_data": {
      "phase_1_result": "Convenient monthly dose achieved",
      "igg_reduction": "Sustained 70-80% IgG reduction over 140+ days vs cyclic pattern with efgartigimod"
    },
    "argx_121_data": {
      "phase_1_result": "Rapid and total IgA depletion",
      "kinetics": "Near-complete IgA depletion within 7 days of single SC dose"
    }
  },
  "catalysts": [
    {
      "event": "3 new Phase 1 programs",
      "timing": "2026",
      "importance": "medium",
      "what_to_watch": "ARGX-118 (Galectin-10), ARGX-125, TSP-101 (Fn14)"
    },
    {
      "event": "ARGX-213 Phase 3 initiation",
      "timing": "2026",
      "importance": "high",
      "what_to_watch": "Next-gen FcRn with monthly dosing entering pivotal development"
    },
    {
      "event": "ARGX-121 PoC data",
      "timing": "TBD",
      "importance": "high",
      "what_to_watch": "IgA Nephropathy proof-of-concept"
    }
  ],
  "investment_analysis": {
    "probability_of_success": "Diversified across multiple mechanisms",
    "peak_sales_estimate": "Multiple $1B+ opportunities across pipeline",
    "key_risks": [
      "Early-stage assets carry higher development risk",
      "Novel mechanisms (MuSK agonist, IgA sweeper) without precedent",
      "Execution across multiple programs requires resources"
    ]
  },
  "strategic_value": {
    "fcrn_franchise": "VYVGART → ARGX-213 (monthly) → ARGX-124 → oral peptides",
    "complement_pillar": "Empasiprubart (C2) for MMN, CIDP, combinations",
    "novel_mechanisms": "MuSK agonist, IgA sweeper, IL-6, Galectin-10, Fn14",
    "vision_2030": "50K patients, 10 labeled indications, 5 new molecules in Phase 3"
  }
}
